Last $9.95 USD
Change Today +0.01 / 0.10%
Volume 381.0K
RPTP On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

raptor pharmaceutical corp (RPTP) Snapshot

Open
$10.12
Previous Close
$9.94
Day High
$10.12
Day Low
$9.75
52 Week High
02/20/14 - $17.72
52 Week Low
05/9/14 - $7.12
Market Cap
632.5M
Average Volume 10 Days
539.4K
EPS TTM
$-0.74
Shares Outstanding
63.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RAPTOR PHARMACEUTICAL CORP (RPTP)

raptor pharmaceutical corp (RPTP) Related Bloomberg News

View More Bloomberg News

raptor pharmaceutical corp (RPTP) Related Businessweek News

No Related Businessweek News Found

raptor pharmaceutical corp (RPTP) Details

Raptor Pharmaceuticals Corp., a biopharmaceutical company, focuses on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. It markets PROCYSBI, a delayed-release capsule used for the management of nephropathic cystinosis in adults and children six years and older in the United States. The company also commercializes PROCYSBI in the 28 member states of the European Commission plus Norway, Liechtenstein, and Iceland. Its clinical development products include RP103 used as a treatment for Huntington's disease; RP103 as a treatment for non-alcoholic fatty liver disease in children; and RP103 as a treatment for mitochondrial disorders, including Leigh syndrome. The company’s other clinical-stage product candidate is Convivia, an oral formulation of 4-methylpyrazole for the treatment of acetaldehyde toxicity resulting from aldehyde dehydrogenase deficiency. Its preclinical programs comprise cysteamine dioxygenase and HepTide for the treatment of hepatocellular carcinoma and other cancers susceptible to induced lysosomal storage. Raptor Pharmaceuticals Corp. has a collaboration agreement with DaVita Clinical Research to screen blood samples from the United States patients with end-stage renal disease to identify patients with unrecognized late-onset nephropathic cystinosis. The company was founded in 2005 and is headquartered in Novato, California.

70 Employees
Last Reported Date: 03/17/14
Founded in 2005

raptor pharmaceutical corp (RPTP) Top Compensated Officers

Co-Founder, Chief Executive Officer, Director...
Total Annual Compensation: $410.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $350.0K
Chief Business Officer
Total Annual Compensation: $292.0K
Chief Medical Officer and Chief Medical Offic...
Total Annual Compensation: $112.8K
Vice President of Finance
Total Annual Compensation: $85.2K
Compensation as of Fiscal Year 2013.

raptor pharmaceutical corp (RPTP) Key Developments

Raptor Pharmaceuticals Corp. Announces Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Year 2014

Raptor Pharmaceuticals Corp. announced unaudited consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company reported net product sales of $23,764,000, loss from operations of $4,231,000, net loss of $6,031,000 or $0.1 per basic and diluted share, non-GAAP loss of $2,456,000 or $0.04 per basic and diluted share compared to the net product sales of $6,603,000, loss from operations of $8,964,000, net loss of $17,277,000 or $0.29 per basic and diluted share, non-GAAP loss of $15,454,000 or $0.26 per basic and diluted share for the same quarter a year ago. For the nine months period, the company reported net product sales of $52,211,000, loss from operations of $24,108,000, net loss of $33,617,000 or $0.54 per basic and diluted share, non-GAAP loss of $24,393,000 or $0.39 per basic and diluted share compared to the net product sales of $6,624,000, loss from operations of $41,237,000, net loss of $57,325,000 or $1.01 per basic and diluted share, non-GAAP loss of $51,905,000 or $0.92 per basic and diluted share for the same period a year ago. The company provided earnings guidance for the year 2014. The company maintaining 2014 global net product sales guidance for PROCYSBI of $65 to $70 million. Narrowing 2014 cash operating expense guidance to $80 to $85 million from $80 to $90 million.

Raptor Pharmaceuticals Corp. to Report Q3, 2014 Results on Nov 06, 2014

Raptor Pharmaceuticals Corp. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 06, 2014

Raptor Pharmaceuticals Corp., Q3 2014 Earnings Call, Nov 06, 2014

Raptor Pharmaceuticals Corp., Q3 2014 Earnings Call, Nov 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RPTP:US $9.95 USD +0.01

RPTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RPTP.
View Industry Companies
 

Industry Analysis

RPTP

Industry Average

Valuation RPTP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.0x
Price/Book 35.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RAPTOR PHARMACEUTICAL CORP, please visit www.raptorpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.